Health Encyclopedia

Coccidioidomycosis - acute pulmonary

Definition

Acute pulmonary coccidioidomycosis is a lung infection caused by breathing in spores of Coccidioides immitis, a fungus found in the soil in certain parts of the southwestern U.S., Mexico, and Central and South America.

Causes, incidence, and risk factors

Coccidioides infection begins in the lungs, following inhalation of the spores. About 60% of infections resolve without ever causing symptoms and are only recognized by a positive coccidioidin skin test.

In the remaining 40% of infections, symptoms range from mild (cold-like or flu-like) to severe (pneumonia). (See coccidioidomycosis.) In less than 1% of infections, widespread disease occurs when the fungus spreads from the lungs through the blood stream to involve the skin, bones, joints, lymph nodes, and central nervous system or other organs.

Individuals of African or Philippine descent, and people with weakened immune systems due to AIDS, diabetes, or immunosuppressive medications, may develop more serious infections. Occasionally the acute infection may develop into a chronic pulmonary (lung) disease or can reactivate after a long latent period.

A history of travel to an endemic region is the key to suspecting coccidioidal infection. Arizona, California (especially San Joaquin Valley), and -- to a lesser extent -- western Texas, are endemic regions in the USA.

Symptoms

Cough
Sputum or phlegm
Chest pain, varies from mild sense of constriction to severe
Fever
Chills
Night sweats
Headache
Muscle stiffness
Muscle aches
Joint stiffness
Rash, may be painful, red, on lower legs (erythema nodosum)
Weight loss
Lymph node swelling

Signs and tests

Sputum smear (KOH test or Papanicolaou stain)
Bronchoscopy with lavage
Biopsy of lymph node or lung (often done with bronchoscopy)

Treatment

The acute disease usually goes away without treatment. Bedrest and treatment of flu-like symptoms until fever disappears may be recommended.

In severe forms of the disease (for example,disseminated coccidioidomycosis), antifungal treatment with amphotericin B, fluconazole, or itraconazole may be needed. The best length of treatment with these medications has not been determined for this disease.

Expectations (prognosis)

The outlook in milder cases is usually good. Disseminated coccidioidomycosis can be serious, particularly in people with weakened immune systems.

Complications

Chronic pulmonary coccidioidomycosis
Disseminated coccidioidomycosis

Calling your health care provider

Symptoms develop that suggest coccidioidomycosis
Symptoms worsen or do not improve with treatment
New symptoms develop

Prevention

Avoiding travel to regions where this fungus is found may prevent risk of developing this disorder. However, this is not practical or possible for many people. It may be prudent to try to avoid contact with soil in these regions if you have a weakened immune system due to HIV or other conditions.

References

Galgiani JN, Ampel NM, Catanzaro A, Johnson RH, Stevens DA, Williams PL. Practice guidelines for the treatment of coccidioidomycosis. Clin Infect Dis. April 2000;30:658-661.

Chiller TM. Coccidioidomycosis. Infect Dis Clin North Am. 2003; 17(1): 41-57, viii.

Murray J, Nadel J. Textbook of Respiratory Medicine. 3rd ed. Philadelphia, Pa: WB Saunders; 2000.

Mandell GL, Bennett JE, Dolin R. Principles and Practice of Infectious Diseases. 5th ed. London, UK: Churchill Livingstone; 2000:2746-2755.

Galgiani JN, Ampel N, Blair JE, et al. Coccidioidomycosis. Clin Infect Dis. 2005;41:1217-23.

Review Date:8/7/2006
Reviewed By:David A. Kaufman, M.D., Assistant Professor, Division of Pulmonary, Critical Care & Sleep Medicine, Mount Sinai School of Medicine, New York, NY. Review provided by VeriMed Healthcare Network.

ADAM Quality A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is the first of its kind, requiring compliance with 53 standards of quality and accountability, verified by independent audit. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial process. A.D.A.M. is also a founding member of Hi-Ethics (www.hiethics.com) and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

The Agency for Health Care Administration (Agency) and this website do not claim the information on, or referred to by, this site is error free. This site may include links to websites of other government agencies or private groups. Our Agency and this website do not control such sites and are not responsible for their content. Reference to or links to any other group, product, service, or information does not mean our Agency or this website approves of that group, product, service, or information.

Additionally, while health information provided through this website may be a valuable resource for the public, it is not designed to offer medical advice. Talk with your doctor about medical care questions you may have.